|1.||Miller, John H: 14 articles (09/2015 - 03/2007)|
|2.||Northcote, Peter T: 13 articles (09/2015 - 03/2007)|
|3.||Kanakkanthara, Arun: 5 articles (09/2015 - 08/2011)|
|4.||Chan, Ariane: 4 articles (06/2015 - 07/2011)|
|5.||Wilmes, Anja: 4 articles (08/2011 - 03/2007)|
|6.||Rawson, Pisana: 3 articles (11/2012 - 08/2011)|
|7.||Singh, A Jonathan: 2 articles (06/2015 - 01/2010)|
|8.||O'Sullivan, David: 2 articles (07/2011 - 10/2009)|
|9.||Rowe, Matthew R: 1 article (09/2015)|
|10.||Teesdale-Spittle, Paul H: 1 article (09/2015)|
09/23/2013 - "Peloruside A analogues 3 and 4 inhibited the proliferation of human cancer cell lines in vitro with micromolar and sub-micromolar IC50 values, respectively. "
01/01/2010 - "Peloruside A was isolated from Mycale hentscheli collected in New Zealand coastal waters, and it already shows promising anti-cancer activity. "
03/01/2008 - "The microtubule-stabilizing agent (+)-peloruside A has emerged as a potential therapeutic agent for the treatment of cancer. "
09/01/2015 - "Peloruside A (PLA) and laulimalide (LAU) are potent microtubule-stabilizing natural products that are effective against a broad spectrum of cancer cells. "
11/01/2013 - "Gene deletion strains hypersensitive to laulimalide and peloruside A represent possible targets for drugs that can synergize with microtubule stabilising agent and be of potential use in combination therapy for the treatment of cancer or other diseases."
10/01/2011 - "We have isolated a series of peloruside A-resistant lines of the human ovarian carcinoma cell line A2780(1A9) to better characterize this binding site and the consequences of altering residues in it. "
07/01/2011 - "Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells."
03/01/2007 - "Ovarian carcinoma cells (1A9) and myeloid leukemic cells (HL-60) were treated with different concentrations of peloruside A and taxoid site drugs, both compounds given singly and in combination in the nanomolar range, and the antiproliferative activity, G2/M blocking potency, and microtubule stabilizing activity of the treatments assessed. "
08/01/2011 - "We developed peloruside A- and laulimalide-resistant cell lines by selecting 1A9 human ovarian carcinoma cells that were able to grow in the presence of one of these agents. "
11/01/2012 - "Acquired resistance to peloruside A and laulimalide is associated with downregulation of vimentin in human ovarian carcinoma cells."
|3.||Breast Neoplasms (Breast Cancer)
|4.||Wounds and Injuries (Trauma)
|5.||Ovarian Neoplasms (Ovarian Cancer)
01/01/2014 - "We recently showed that peloruside A (PLA) and laulimalide (LAU)-resistant cancer cell lines, 1A9-R1 (R1) and 1A9-L4 (L4), generated through multi-step selection of human 1A9 ovarian cancer cells with high concentrations of either PLA (for R1) or LAU (for L4) have single distinct mutations in their βI-tubulin gene. "
|1.||Heterologous Transplantation (Xenotransplantation)